- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01940757
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
An Experimental Infection Study of Dermally-applied Infectious Necator Americanus Hookworm Larvae in Hookworm-naïve Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Open-label, dose-escalation clinical study in healthy, hookworm-naïve adults:
- Study site: George Washington Medical Faculty Associates, Washington, DC
- Number of participants: up to 30 in 3 cohorts of 10 volunteers each
In Cohort 1, ten (10) volunteers will receive an inoculum of 25 infectious Necator americanus larvae. In Cohort 2, ten (10) volunteers will receive an inoculum of 50 infectious Necator americanus larvae. In the optional Cohort 3, ten (10) volunteers will receive an inoculum of 75 infectious Necator americanus larvae.
The cohorts will be enrolled in a staggered fashion with safety data assessed prior to larval dose escalation. Cohort 2 will be inoculated no earlier than 8 weeks after the last volunteer is inoculated in Cohort 1. The optional Cohort 3 will be inoculated no sooner than 8 weeks after the last volunteer is inoculated in Cohort 2. Cohort 3 will be enrolled only if the tolerability of the experimental infection of Cohort 2 is acceptable and does not result in significant adverse events.
Within each cohort, after Study Day 70, but before Study Day 77, up to 5 volunteers will undergo capsule endoscopy in order to visualize and count adult N. americanus hookworms residing in the intestine. Informed consent for capsule endoscopy will be obtained separately from the primary study, and agreement or refusal will not impact on a subject's eligibility to enroll or continue participation in the primary study.
Three months after larval administration, or at the time of study withdrawal, all participants will receive a 3-dose treatment of albendazole (400 mg per dose) for clearance of experimental infection.
- Larval inoculum schedule: Study Day 0 (single application)
- Route: applied to intact skin on the volar aspect of forearm
- Doses of N. americanus Larval Inoculum to be tested: 25, 50 and 75 infectious larvae (high dose optional)
- Study duration: 6 months per study participant; total duration of the study estimated at approximately 13 months
- Anthelmintic treatment: 3 months post larval inoculum, or at study withdrawal, 3-dose treatment with 400 mg albendazole
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Study Coordinator
- Phone Number: (202) 994-1599
- Email: gwvru@gwu.edu
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Recruiting
- George Washington University Medical Faculty Associates
-
Sub-Investigator:
- Aimee Desrosiers, PA
-
Sub-Investigator:
- Elissa Malkin, DO, MPH
-
Sub-Investigator:
- Caroline Thoreson, PA
-
Contact:
- Study Coordinator
- Phone Number: 202-994-1599
- Email: gwvru@gwu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males or females between 18 and 45 years, inclusive.
- Good general health as determined by means of the screening procedure.
- Available for the duration of the trial (6 months).
- Willingness to participate in the study as evidenced by signing the informed consent document.
Exclusion Criteria:
- Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female).
- Participant unwilling to use reliable contraception methods while participating in the study (if female and not surgically sterile, abstinent or at least 2 years post-menopausal).
- Currently lactating and breast-feeding (if female).
- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies.
- Known or suspected immunodeficiency.
- Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25-times the upper reference limit).
- Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing).
- Laboratory evidence of hematologic disease (hemoglobin <11.5 g/dl [females] or <12.5 g/dl [males]; absolute leukocyte count <3.6 or >10.7 x 103/mm3; absolute neutrophil count [ANC] <1.7 x 103/mm3; absolute lymphocyte count <0.7 x 103/mm3; or platelet count <140 x 103/mm3).
- History of iron deficiency anemia.
- History of hypoalbuminemia.
- Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper reference limit).
- Serum glucose (random) greater than 1.2-times the upper reference limit.
- Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
- Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
- History of a severe allergic reaction or anaphylaxis.
- Severe asthma as defined by the need for daily use of inhalers or emergency clinic visit or hospitalization within 6 months of the volunteer's expected Day 0 of the study.
- Positive ELISA for hepatitis B surface antigen (HBsAg).
- Positive confirmatory test for HIV infection.
- Positive confirmatory test for hepatitis C virus (HCV) infection.
- Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of the volunteer's expected Day 0 of this study or planned use during the study.
- Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to the volunteer's expected Day 0 of the study.
- Receipt of blood products within the past 6 months.
- Known allergy to amphotericin B or gentamicin.
- History of previous infection with hookworm or residence for more than 6 months in a hookworm-endemic area.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 25 Necator americanus Hookworm Larvae
|
Infectious larvae of the human hookworm Necator americanus
Other Names:
|
Experimental: 50 Necator americanus Hookworm Larvae
|
Infectious larvae of the human hookworm Necator americanus
Other Names:
|
Experimental: 75 Necator americanus Hookworm Larvae
|
Infectious larvae of the human hookworm Necator americanus
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study product-related adverse events
Time Frame: Up to 6 months after dosing
|
Frequency of study product-related adverse events, graded by severity, for different doses of N. americanus Larval Inoculum.
|
Up to 6 months after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fecal egg counts
Time Frame: Up to Study Day 101
|
To determine the dose of N. americanus Larval Inoculum that generates the highest fecal egg counts, measured by fecal microscopy.
|
Up to Study Day 101
|
Number of adult hookworms in feces post-treatment
Time Frame: Study Days 87-101
|
To compare the N. americanus Larval Inoculum dose received with the number of adult worms present in the gut, as determined by capsule endoscopy.
|
Study Days 87-101
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David J Diemert, MD, George Washington University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SVI-CH-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hookworm Infection
-
Baylor College of MedicineNational Institute of Allergy and Infectious Diseases (NIAID); George Washington...Active, not recruitingHookworm InfectionsUnited States
-
Baylor College of MedicineJohns Hopkins University; University of California, San Francisco; George Washington... and other collaboratorsCompletedHookworm Infection | Hookworm DiseaseBrazil
-
Baylor College of MedicineCompletedHookworm Infection | Hookworm DiseaseGabon
-
Baylor College of MedicineGeorge Washington University; Amsterdam Institute for Global Health and Development and other collaboratorsCompletedHookworm Infection | Hookworm DiseaseGabon
-
Baylor College of MedicineCompletedHookworm Infection | Hookworm DiseaseBrazil
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriCompletedHookworm InfectionsTanzania
-
Albert B. Sabin Vaccine InstituteLondon School of Hygiene and Tropical Medicine; George Washington University; Oswaldo Cruz FoundationTerminatedHookworm InfectionBrazil
-
Baylor College of MedicineGeorge Washington University; Children's National Research InstituteCompletedHookworm Infection | Hookworm DiseaseUnited States
-
Brugmann University HospitalUniversité Libre de BruxellesActive, not recruiting
-
Swiss Tropical & Public Health InstitutePublic Health Laboratory Ivo de CarneriCompletedHookworm InfectionsTanzania
Clinical Trials on Necator americanus Hookworm Larvae
-
James Cook University, Queensland, AustraliaNational Health and Medical Research Council, Australia; The Prince Charles... and other collaboratorsCompleted
-
Meta RoestenbergCompleted
-
University of NottinghamNational Multiple Sclerosis SocietyCompletedMultiple Sclerosis, Relapsing-RemittingUnited Kingdom
-
The Prince Charles HospitalNational Health and Medical Research Council, AustraliaCompleted
-
Leiden University Medical CenterCompletedEstablishing a Controlled Human Hookworm Infection Model at Leiden University Medical Center (CHHIL)Necator Americanus InfectionNetherlands
-
University of NottinghamWithdrawnMultiple SclerosisUnited Kingdom
-
University of NottinghamCompleted
-
University of NottinghamCompletedAllergy | Rhinitis, Allergic, Perennial | HayfeverUnited Kingdom
-
Princess Alexandra Hospital, Brisbane, AustraliaThe Broad Foundation; James Cook University, Queensland, Australia; Townsville... and other collaboratorsCompleted
-
Baylor College of MedicineNational Institute of Allergy and Infectious Diseases (NIAID); George Washington...Active, not recruitingHookworm InfectionsUnited States